Ingrid Mayer
Faculty Member
Last active: 3/23/2014

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA, National Comprehensive Cancer Network
J Natl Compr Canc Netw. 2012 10 (7): 821-9

PMID: 22773798 · PMCID: PMC3753191 · DOI:10.6004/jnccn.2012.0086

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

MeSH Terms (8)

Antineoplastic Agents, Hormonal Biomarkers, Tumor Breast Neoplasms Female Humans Neoplasm Metastasis Protein Kinase Inhibitors TOR Serine-Threonine Kinases

Connections (1)

This publication is referenced by other Labnodes entities:

Links